Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00362102
First received: August 8, 2006
Last updated: November 21, 2016
Last verified: November 2016